In ARMS, FGFR4 is a direct target gene of the fusion protein PAX3-FOXO1 [41], and in ERMS FGFR4 is frequently amplified with 12% of the tumors harboring activating mutations of the receptor [42,43,44]. Here, FGFR4 is linked to alveolar rhabdomyosarcoma.